(1) Role of the sympathoadrenal system in hypertension, postural adaptation, and long-term cardiovascular adaptation (2) Control of regional and systemic blood flow during acute stress responses (3) Mechanisms of stress responses and vasoreactivity, both in vivo and in vitro, including metabolic interactions (4) Cardiovascular drug effects (5) Outcomes of drug therapies
Education and Training:
Staff Associate, Experimental Therapeutics Section, Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute (1979)
Attending Physician, Clinical Center, National Institutes of Health (1979)
Internship, Straight Medicine, Barnes Hospital, Washington University (1974)
MD, Internal Medicine, Johns Hopkins University (1972)
AB, Biology/Biochemistry, Princeton University (1968)
Employment:
Chief of Medicine, Erie County Medical Center (2004-present)
Professor of Pharmacology and Toxicology, University at Buffalo (1991-present)
Professor of Medicine, University at Buffalo (1990-present)
Associate Program Director, Internal Medicine Training Program, University York at Buffalo (2004–2008)
Vice Chair for Research, Department of Medicine, State University of New York at Buffalo (1999–2006)
Director, FDA Clinical Pharmacology Fellowship Training Program, University at Buffalo (1992–2002)
Program Director, Internal Medicine Training Program B, State University of New York at Buffalo (1988–2001)
Chairman, Department of Medicine, Millard Fillmore Health System (1988–1998)
Adjunct Associate Professor of Medicine, University of Rochester School of Medicine (1988–1991)
Associate Professor, University at Buffalo (1988–1990)
Associate Professor; Attending Physician, Department of Medicine, University of Rochester School of Medicine (1984–1988)
Director, Hypertension Service, University of Rochester School of Medicine (1980–1988)
Assistant Professor of Medicine; Associate Physician, (Nephrology), University of Rochester School of Medicine, School of Medicine (1979–1984)
Guest Worker, Experimental Therapeutics Section, Hypertension Endocrine Branch, National Heart, Lung and Blood Institute, National Institutes of Health (1979–1980)
Staff Associate, Experimental Therapeutics Section, Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute, NIH Bethesda, Maryland (1975–1979)
Attending Physician, National Institutes of Health Bethesda Maryland (1975–1979)
Physician, part time, Urgent Care Clinic, Columbia Medical Group (1975–1978)
Consultant in Emergency Medicine and Acting Assistant Director of Emergency Services, Howard County General Hospital (1974–1975)
Lecturer in Medicine, School of Health Services, Johns Hopkins University (1974–1975)
Intern and Assistant Resident, Straight Medicine, Washington University, Barnes Hospital (1972–1974)
American Society of Hypertension, Marvin Moser Clinical Hypertension Award (2012)
Who's Who (2011)
American Society of Hyptertension, Fellow (2010)
American Society of Hyptertension, Hypertension Specialist (1999)
Best Doctors in America (1996)
American Heart Association, Fellow (1995)
American College of Physicians, Fellow (1990)
Who's Who in Science (1984)
Who's Who in the East (1984)
Fellow, High Blood Pressure Research Council, AHA (1984)
Sinsheimer Scholar Award (1982)
Clinical Associate Physician Award, University of Rochester (1979)
Buswell Fellow, University of Rochester (1979)
National Merit Scholarship Finalist (1964)
Hearst Foundation Senate Youth Fellow (1964)
Research Expertise:
New Research Expertise
Grants and Sponsored Research:
June 2001–December 2002 Hemodynamic Profiling of Carvedilol Glaxo Smith-Kline Role: Principal Investigator $195,000
October 1992–September 2002 Pilot Clinical Pharmacology Training Program US Food and Drug Administration and USPHS Role: Principal Investigator $2,055,000
January 1989–December 1994 Coronary Arrhythmia Suppression Trial NHLBI, NIH Role: Principal Investigator $125,000
January 1986–January 1988 Seasonal Blood Pressure Variation American Heart Association, NYS Affiliate Role: Principal Investigator $49,000
Joseph Izzo. Aging and systolic hypertension: cluster patterns and problem-solving strategies to answer the genetic riddle (editorial). Hypertension. 2001; 37.
Allen, K., Shykoff, B.E., Joseph Izzo. Pet ownership, but not ACE inhibitor therapy, blunts home blood pressure responses to mental stress. Hypertension. 2001; 38.
Joseph Izzo, Manning, T.S., Shykoff, B.E.. Office blood pressures, arterial compliance characteristics, and estimated cardiac load. Hypertension. 2001; 38.
Chow, S.L., Luzier, A.B., DiTusa, L., Snyder, B.D., Joseph Izzo. Acid suppressive therapy use associated with antihypertensive agents. Pharmacoepidemiology. 2001; 41.
DiTusa L, Luzier AB, Jarosz DE, Snyder BD, Joseph Izzo. Treatment of hypertension in a managed care setting.. Am J Manag Care. 2001; 7(5).
Joseph Izzo, Shykoff, B.E.. Arterial stiffness: clinical relevance, measurement, and treatment. Reviews in Cardiovascular Medicine. 2001; 2.
Chaudhuri, A. and Izzo, J.L. Jr.. Insulin resistance and hypertension in the absence of subcutaneous fat. Reviews in Cardiovascular Medicine. 2001; 1.
Izzo, J.. A Challenge to JNC VI: Should guidelines for treatment be modified? Blood pressure guidelines and tight blood pressure control is essential. Medical Crossfire. 2000; 2(9).
Izzo, J.. Systolic hypertension, arterial stiffness and vascular damage: Role of the renin-angiotensin system. Blood Pressure Monitoring. 2000; 5(suppl).
Joseph Izzo. Vascular disease and the renin-system in the patient with hypertension: panel discussion and questions to the audience. Blood Pressure Monitoring. 2000; 5(suppl).
Izzo, J.. The role of the renin-angiotensin system in vascular health. Use of ACE inhibition to improve vascular function. Heart Disease. 2000; 2(5).
Joseph Izzo, Levy D, Black HR. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans.. Hypertension. 2000; 35(5).
Huang MH, Knight PR, Joseph Izzo. Ca2+-induced Ca2+ release involved in positive inotropic effect mediated by CGRP in ventricular myocytes.. Am J Physiol. 1999; 276(1 Pt).
Huang, M., Knight, P., Joseph Izzo. Ionotropic mechanisms of calcitonin gene-related peptide in isolated ventricular myocytes. Am J Physiol. 1999; 276.
Joseph Izzo. Risk stratification: a key to managing hypertension in the managed care setting. Am J Managed Care. 1999; 5(Suppl).
Bong Sung, Joseph Izzo, Paresh Dandona, Michael Wilson. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999; 34.
Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Joseph Izzo. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.. Am J Cardiol. 1998; 82(4).
Sung BH, Ching M, Joseph Izzo, Dandona P, Wilson MF. Insulin-mediated venodilation is impaired in patients with high cholesterol.. Hypertension. 1998; 31(6).
Joseph Izzo. The microcirculation in hypertension. Current Concepts in Hypertension. 1998; 2(3).
Ching MI, Sung BH, Forrest A, Wilson MF, Izzo JL. Vasoreactivity in pre- and postmenopausal women: evaluation by pharmacodynamic modeling.. J Clin Pharmacol. 1998; 38(2).
Bong Sung, Ching, M., Joseph Izzo, Paresh Dandona, Michael Wilson. Insulin-mediated venodilation is impaired in patients with high cholesterol. Hypertension. 1998; 31.
Hawari, F., Shyoff, B., Joseph Izzo. Heparin attenuates norepinephrine-induced vasoconstriction by a cyclic-GMP-mediated mechanism. Vascular Medicine. 1998; 3.
Sung BH, Wilson MF, Izzo JL, Ramirez L, Dandona P. Moderately obese, insulin-resistant women exhibit abnormal vascular reactivity to stress.. Hypertension. 1997; 30(4).
Sung BH, Izzo JL, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol.. Am J Hypertens. 1997; 10(6).
Carr JR, Fitzpatrick P, Izzo JL, Cumbo TJ, Birmingham MC, Adelman MH, Paladino JA, Hanson SC, Schentag JJ. Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System.. Infect Control Hosp Epidemiol. 1997; 18(4).
Creager, M.A., Joseph Izzo. Coronary and peripheral vasoreactivity: role of endothelial dysfunction. Current Concepts in Hypertension. 1997; 2(2).
Joseph Izzo. Vasoreactivity and high risk hypertension. Current Concepts in Hypertension. 1997; 2(2).
Harris LM, Faggioli GL, Shah R, Koerner N, Lillis L, Dandona P, Izzo JL, Snyder B, Ricotta JJ. Vascular reactivity in patients with peripheral vascular disease.. Am J Cardiol. 1995; 76(3).
Grover A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P. Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study.. Hypertension. 1995; 25(4 Pt).
Izzo JL, Swislocki AL. Workshop III--Insulin resistance: is it truly the link?. Am J Med. 1991; 90(2A).
Izzo JL, Larrabee PS, Sander E, Lillis LM. Hemodynamics of seasonal adaptation.. Am J Hypertens. 1990; 3(5 Pt).
Izzo JL, Sander E, Larrabee PS. Effect of postural stimulation on systemic hemodynamics and sympathetic nervous activity in systemic hypertension.. Am J Cardiol. 1990; 65(5).
Izzo JL. Sympathoadrenal activity, catecholamines, and the pathogenesis of vasculopathic hypertensive target-organ damage.. Am J Hypertens. 1989; 2(12 Pt).
Izzo JL. The sympathoadrenal system: friend and foe?. Am J Hypertens. 1989; 2(12 Pt).
Licht MR, Izzo JL. Humoral effect of norepinephrine on renin release in humans.. Am J Hypertens. 1989; 2(10).
Izzo JL, Smith RJ, Larrabee PS, Kallay MC. Plasma norepinephrine and age as determinants of systemic hemodynamics in men with established essential hypertension.. Hypertension. 1987; 9(4).
Blair ML, Chen YH, Izzo JL. Influence of renal perfusion pressure on alpha- and beta-adrenergic stimulation of renin release.. Am J Physiol. 1985; 248(3 Pt).
Chen YH, Blair ML, Izzo JL. Renal norepinephrine overflow during graded renal nerve stimulation before and after beta-adrenoceptor blockade.. J Auton Nerv Syst. 1984; 11(3).
Daugirdas JT, Ing TS, Chen WT, Vestal RE, Izzo JL, Hano JE, Norusis MJ. Hemodynamic responses to volume depletion in uremic dogs on maintenance hemodialysis.. Am J Physiol. 1984; 247(2 Pt).
Izzo JL, Horwitz D, Lawton WJ, Keiser HR. Fludrocortisone suppression of sympathetic nervous activity.. Clin Pharmacol Ther. 1983; 33(1).
Joseph Izzo. Renovascular hypertension: diagnostic problems and therapeutic implications. JAMA. 1983; 249.
Joseph Izzo, Greulich, D. Radioenzymatic assay for plasma dihydroxyphenylglycol, dihydroxymandelic acid and dihydroxyphenyl acetic acid in plasma. Life Sci. 1983; 33.
Joseph Izzo. Cardiovascular hormonal effects of circulating norepinephrine. Hypertension. 1983; 5.
Joseph Izzo, Sterns, RH. Abnormal norepinephrine release in uremia. Kidney International. 1983; 24(Suppl).
Joseph Izzo, Horwitz, D., Lawton, W.J., Keiser, H.R.. Fluorocortisone suppression of synpathetic nervous activity. Clin. Pharmacol. Ther.. 1983; 33.
Joseph Izzo, Ghosal, A., Kwong, T., Freeman, R.B., Jaenike, J.R.. Age and prior caffeine use alter the cardiovascular and adrenomedullary responses to oral caffeine. Am. J. Cardiology. 1983; 52.
Colgan, F.J., Sawa, T., Ten Eyck, L.G., Joseph Izzo. Protective effects of beta blockade on pulmonary function when intracranial pressure is elevated. Crit. Care Medicine. 1983; 11.
Joseph Izzo, Izzo, MS, Sterns, RH, Freeman, RB. Sympathetic nervous hyperactivity in maintenance hemodialysis patients. Transactions American Society Artificial Internal Organs. 1982; 28.
Daugirdas, JT, Ing, TS, Chen, WT, Vestal, RE, Joseph Izzo, Hano, JE, Liu, P. Ultrafiltration hemodynamics in conscious, uremic dogs: effect of using a bicarbonate-buffered, plasma-resembling dialysate. Trans Am Soc Artif Int Organs. 1982; 28.
Joseph Izzo. Hypertension in the elderly: a pathophysiological approach to therapy. J Am Geriatrics Soc. 1982; 30.
Gutierrez OH, Izzo JL, Burgener FA. Transluminal recanalization of an occluded renal artery: reversal of anuria in a patient with a solitary kidney.. AJR Am J Roentgenol. 1981; 137(6).
Goldstein DS, Feuerstein G, Izzo JL, Kopin IJ, Keiser HR. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man.. Life Sci. 1981; 28(5).
Izzo JL, Horwitz D, Keiser HR. Physiologic mechanisms opposing the hemodynamic effects of prazosin.. Clin Pharmacol Ther. 1981; 29(1).
Goldstein DS, Harris AH, Izzo JL, Turkkan JS, Keiser HR. Response of plasma catecholamines and renin during operantly conditioned blood pressure elevations in baboons.. Physiology and Behavior. 1981; 26(1).
Nesbitt GH, Izzo J, Peterson L, Wilkins RJ. Canine hypothyroidism: a retrospective study of 108 cases.. J Am Vet Med Assoc. 1980; 177(11).
Izzo JL, Roncone AM, Helton DL, Izzo MJ. Subcellular distribution of intraportally injected 125I-labeled insulin in rat liver.. Arch Biochem Biophys. 1979; 198(1).
Izzo JL, Horwitz D, Keiser HR. Reduction in human urinary MHPG excretion by guanethidine: urinary MHPG as index of sympathetic nervous activity.. Life Sci. 1979; 24(15).
Vinci JM, Zusman RM, Izzo JL, Bowden RE, Horwitz D, Pisano JJ, Keiser HR. Human urinary and plasma kinins: relationship to sodium-retaining steroids and plasma renin activity.. Circ Res. 1979; 44(2).
Vinci JM, Gill JR, Bowden RE, Pisano JJ, Izzo JL, Radfar N, Taylor AA, Zusman RM, Bartter FC, Keiser HR. The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition.. J Clin Invest. 1978; 61(6).
Izzo JL, Izzo MS, Sterns RH, Freeman RB. Sympathetic nervous system hyperactivity in maintenance hemodialysis patients.. Trans Am Soc Artif Intern Organs. ; 28.
Vinci JM, Zusman RM, Izzo JL, Bowden RE, Horwitz D, Pisano JJ, Keiser HR. Relationship of human urinary and plasma kinins to sodium-retaining steroids and plasma renin activity.. Adv Exp Med Biol. ; 120B.
Izzo J. Cardiovascular hormonal effects of circulating norepinephrine.. Hypertension. ; 5(5).
Izzo JL. The sympathoadrenal system in the maintenance of elevated arterial pressure.. J Cardiovasc Pharmacol. ; 6 Sup.
Izzo JL, Santarosa RP, Larrabee PS, Smith RJ, Kallay MC. Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine.. J Cardiovasc Pharmacol. ; 10 Su.
Zambraski EJ, Ciccone CD, Izzo JL. The role of the sympathetic nervous system in 2-kidney DOCA-hypertensive Yucatan miniature swine.. Clin Exp Hypertens A. ; 8(3).
Allen K, Golden LH, Joseph Izzo, Ching MI, Forrest A, Niles CR, Niswander PR, Jared Barlow. Normalization of hypertensive responses during ambulatory surgical stress by perioperative music.. Psychosom Med. ; 63(3).
Hollenberg NK, Joseph Izzo, Sica DA, White WB, Mansoor GA. Vascular disease and the renin-angiotensin system in the patient with hypertension: panel discussion and questions from the audience.. Blood Press Monit. ; 5 Sup.
Joseph Izzo. Systolic hypertension, arterial stiffness, and vascular damage: role of the renin-angiotensin system.. Blood Press Monit. ; 5 Sup.
Shykoff BE, Hawari FI, Izzo JL. Diameter, pressure and compliance relationships in dorsal hand veins.. Vasc Med. ; 6(2).
O'Donovan RM, Gutierrez OH, Izzo JL. Preservation of renal function by percutaneous renal angioplasty in high-risk elderly patients: short-term outcome.. Nephron. ; 60(2).
Izzo JL; Sica,D.A.; Black, H.R.. Hypertension Primer, Fourth Edition. 2008.
Izzo JL; Black, H.R.. Hypertension Primer, Third Edition. 2003.
Izzo JL, Black, H.R.. Hypertension Primer, Second Edition. 1999.
Joseph Izzo, Black, H.R., Taubert, K.. Hypertension Primer. 1993.
Joseph Izzo. Angiotensin converting enzyme inhibition. 1983.
Professional Memberships:
American Society of Hypertension; Ad hoc advisory group for organizational strategic planning (2013)
American Society of Hypertension; Fellow of the American Society of Hypertension (2010)
American Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, New York initiatives (2009)
Amercian Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, San Francisco initiatives (2008)
American Society of Hypertension; Hypertension Education Development Group (2007–2010)
American Society of Hypertension; Scientific Publications and Clinical Advisory Committee (2007–2009)
American Society of Hypertension; Physician Leader and founder, ASH Community Outreach Programs, New Orleans initiatives (2007)
American Society of Hypertension; Treasurer (2006–2009)
American Society of Hypertension; Executive Committee (2006–2009)
American Society of Hypertension; Finance Committee (Chair) (2006–2009)
American Heart Association - National Organization; Ischemic Heart Disease Guideline Development Group (2006–2007)
American Society of Hypertension; Scientific Program Committee (2005–2008)
American Society of Hypertension; Executive Council (2005–2006)
American Society of Hypertension; Conflict of Interest Study Committee (2004–2006)
American Society of Hypertension; Board of Directors (2003–2009)
Amercian Heart Association - Council for High Blood Pressure Research; Finance Committee (2003–2005)
American Heart Association - National Organization; Medical Editorial Board (2002)
Amercian Heart Association - Council for High Blood Pressure Research; Scientific Sessions Program Committee (2001–2004)
American Society of Hypertension; Continuing Medical Education Committee (2001–2004)
American Heart Association - National Organization; Fellow of the American Heart Association (2001)
United States Pharmacopeia; USP Counsel of Experts, Cardiovascular and Renal Drugs Expert Committee (2000–2005)
American Society of Hypertension; National Specialist Examination Subcommittee (1999–2005)
American Society of Hypertension; Specialist Committee (1999–2001)
Amercian Society of Hypertension; Nominating Committee (1999–2000)
American Society of Hypertension; Professional Education Committee member (1998–2004)
American Heart Association - National Organization; Continuing Education Committee (AHA National Committee) (1997–2000)
American College of Physicians; Councilor for Upstate Region (New York State Chapter) (1996–2000)
Amercian Heart Association - Council for High Blood Pressure Research; Publications Committee (1996–1999)
United States Pharmacopeia; USP Revisions Panel for Cardiorenal Drugs, 1995-2000 (1995–2000)
American Heart Association - National Organization; Expert Panel on Cardiovascular Drugs (1994–2004)
Council on Geriatric Cardiology; Fellow (1994–2000)
Amercian Society for Clinical Pharmacology and Therapeutics; Chairman, Hypertension Section (1994–1997)
Buffalo Academy of Medicine; President (1994–1996)
Amercian Heart Association - Council for High Blood Pressure Research; Professional Education Committee Chairman (1993–1996)
Amercian Heart Association - Council for High Blood Pressure Research; Executive Committee member (1993–1996)
Amercian Heart Association - Council for High Blood Pressure Research; Long Range Planning Committee member (1993–1996)
Amercian Autonomic Society; Member (1992–2004)
Amercian Heart Association - Council for High Blood Pressure Research; Scientific Program Abstract Grader (1992)
Society for Vascular biology and Medicine; Member (1990–2002)
American Society for Clinical Pharmacology and Therapeutics; Abstract Reviewer (1990–1993)
American Society for Clinical Pharmacology and Therapeutics; Co-Chairman, Hypertension Section (1990–1993)
Amercian Heart Association - Council for High Blood Pressure Research; Chairman, Hypertension Curriculum Committee (1990–1991)
Association of Program Directors of Internal Medicine; Member (1988–2001)
Buffalo Academy of Medicine; Member (1988–1998)
American Society of Nephrology; Chairman, Hypertension Section (1987)
Amercian Heart Association - Council for High Blood Pressure Research; Professional Education Committee Member (1986–1993)
American Society of Hypertension; Scientific Program Abstract Grader (1986)
National Kidney Foundation of Upstate New York; Medical Advisory Board (1985–1987)
National Kidney Foundation of Upstate New York; Chairman, Scientific Grant Review Committee (1985–1987)
American Society of Nephrology; Scientific Program Abstract Grader (1984–1986)
Interantional Society for Hypertension; Member (1984)
Amercian Heart Association - Council for High Blood Pressure Research; Fellow (1983)
American Society of Hypertension; Founding Member (1983)
International Scoiety of Nephrology; member (1982–1993)
New York Academy of Sciences; Member (1982–1984)
Amercian Heart Association - NYS Affiliate; Hypertension Committee (1982–1984)
Amercian Heart Association - Council on the Kidney in Cardiovascular Disease; Member (1982)
Amercian Association for the Advancement of Science; Member (1981–1984)
American Federation for Biomedical Research; Member (1980–2000)
Inter-American Society for Hypertension; Member (1980)
American Society of Nephrology; Member (1979–2002)
Presentations:
"Estrogen may influence blood pressure regulation" Thirteenth Scientific Meeting of the American Society of Hypertension, American Society of Hypertension (1998)
"Normalization of hypertensive responses during ambulatory surgical stress by perioperative music" Thirteenth Scientific Meeting of the American Society of Hypertension (1998)
Service Activities:
Faculty Senate; Member (2001)
Biochemistry, School of Medicine & Biomedical Sciences Sample Committee; Member (1999)
Biochemistry, School of Medicine & Biomedical Sciences Sample Committee; Member (1999)
Biochemistry, School of Medicine & Biomedical Sciences Sample Committee; Chair (1999)
School of Medicine & Biomedical Sciences Faculty Council; Alternate Member (1998–2002)
School of Medicine & Biomedical Sciences Faculty Council; Member (1989)
Combined ARB_neprolysin (LCZ) in Systolic Hypertension; Combined ARB-neprolysin (LCZ) in Systolic Hypertension; International Principal Investigator and Chair,Executive Committee, Novartis Pharmaceuticals (2011–2013)
Visiting Professorship; New York University (Cardiology); Visiting Professor (2009)
Visiting Professorship; SUNY-Brooklyn (Medicine and Endocrinology); Visiting Professor (2008)
Visiting Professorship; Temple University (Cardiology); Visiting Professor (2008)
TRINITY (Triple Combination therapy in Hypertension); TRINITY(Triple Combination therapy in Hypertension)Study Executive Committee and National Principal Investigator , Daiichi-Sankyo (2008–2010)
Visiting Professorship; University of Mississippi (Medicine and Pharmacology); Visiting Professor (2007)
Visiting Professorship; Tufts University (Cardiology); Visiting Professor (2007)
VALVET; VALVET (Valsartan-hydrochlorothiazide combination in Very Elderly Subjects with Essential Hypertension)Executive Committee and National Principal Investigator (2007–2013)
Visiting Professorship; Emory University (Cardiology and Medicine); Visiting Professor (2007)
Visiting Professorship; Tulane University (Physiology); Visiting Professor (2006)
EXFAST; EXFAST (Exforage and Systolic Hypertension) Study Executive Committee and National Principal Investigator, Novartis (2006–2008)
EXCEED; EXCEED (Exforage and Diastolic Dysfunction)Study Executive Committee, Novartis (2006)
Visiting Professorship; Medical College of Ohio (Medicine); Visiting Professor (2005)
Visiting Professorship; Yale University (Cardiothoracic Surgery); Visiting Professor (2004)
Visiting Professorship; University of Pittsburgh (Cardiology); Visiting Professor (2004)
Visiting Professorship; University of Rochester (Cardiology); Visiting Professor (2003)
Visiting Professorship; university of Rochester (Cardiology); Visiting Professor (2003)
Visiting Professorship; University Medical Center of South Neveda (Medicine); Visiting Professor (2003)
Visiting Professorship; University of Rochester (Cardiology); Visiting Professor (2003)
Visiting Professorship; George Washington University (Pharmacology); Visiting Professor (2003)
Visiting Professorship; SUNY at Syracuse (Nephrology); Visiting Professor (2003)
Visiting Professorship; University of Western Ontario (Clinical Pharmacology); Visiting Professor (2003)
ValMARC; ValMARC (Valsartan and CRP)Study Executive Committee; Committee Member (2003–2005)
ROADMAP; ROADMAP (Randomized Olmesartan And Diabetic Microalbuminuria Prevention) Study Executive Committee, Daiichi-Sanko (2003)
Visiting Professor; SUNY-Brooklyn (Endocrinology), 12/01; Visiting Professor (2001)
Visiting Professorship; University of Western Ontario (Clinical Pharmacology); Visiting Professor (2001)
Visiting Professor; Mount Sinai School of Medicine (Hypertension), 2/01; Visiting Professor (2001)
AMAZE; AMAZE ("Antihypertensive Efficacy of Adding Candesartan Cilexetil to Lisinopril in Comparision to Up-Titration of Lisinopril:A Multi-Center Trial Using Atacand-Zestril to Evaluate the Efects on Lowering Blood Pressure,"
National Lead Investigator; National Liaison (2001–2002)
Visting Professorship; University of California, San Francisco (Cardiology) 12/00; Visiting Professor (2000)
Visiting Professor; Long Island Jewish Medical Center (General Medicine), 11/00; Visiting Professor (2000)
Visiting Professorship; University of Connecticut Health Center (Hypertension); Visiting Professor (2000)
Visiting Professorship; University of Western Ontario (Clinical Pharmacology); Visiting Professor (2000)
Visiting Professorship; Medical College of Wisconsin (Hypertension); Visiting Professor (2000)
Visiting Professorship; University of Connecticut Health Center (Hypertension); Visiting Professor (2000)
Visiting Professorship; SUNY at Syracuse (Nephrology); Visiting Professor (2000)
Visiting Professorship; University of Hawaii (Medicine); Visiting Professor (2000)
Visiting Professorship; University of Pittsburgh (Cardiology); Visiting Professor (2000)
Visiting Professorship; Rush Medical College (Preventive Medicine); Visiting Professor (2000)
New Service Activity; Boy Scouts of America Merit Badge Counselor; Volunteer (2000)
Visiting Professorship; University of Calgary (Cardiology and Physiology); Visiting Professor (1999)
Visiting Professorship; University of Edmonton (Cardiology); Visiting Professor (1999)
Visiting Professorship; Rush Medical College (Preventive Medicine); Visiting Professor (1999)
TROPHY (Trial of Prevention of Hypertension); (Trial of Prevention of Hypertension) Study, Data Safefty Monitoring Board, Astra
Zeneca; Board Member (1999–2005)
Editorial Board; Reviews in Cardiovascular Medicine; Editorial Board Member (1999–2001)
Editorial Board; Journal of Clinical Hypertension; Editorial Board Member (1999)
Visiting Professorship; Wayne State University (Endocrinology); Visiting Professor (1998)
Visiting Professorship; Albany Medical College (Medicine); Visiting Professor (1997)
Visiting Professorship; Albany Medical College (Cardiology); Visiting Professor (1997)
Visiting Professorship; Northeastern Ohio Consortium (Medicine); Visiting Professor (1997)
Visiting Professorship; Susquehanna Health System (Medicine); Visiting Professor (1996)
Visiting Professorship; University of Illinois-Peoria (Clinical Pharmacology); Visiting Professor (1996)
Visiting Professorship; Albany Medical College (Cardiology and Medicine); Visiting Professor (1995)
Visiting Professorship; Meharry Medical College (Clinical Pharmacology); Visiting Professor (1994)
New Service Activity; Fellow, Council on Geriatric Cardiology; Member (1994)
Visiting Professorship; Albany Medical College(Cardiology); Visiting Professor (1993)
Visiting Professorship; Thomas Jefferson University (Clinical Pharmacology); Visiting Professor (1993)
Visiting Professorship; Tulane University (Cardiology); Visiting Professor (1993)
Visiting Professorship; University of Western Ontario (Clinical Pharmacology); Visiting Professor (1993)
Visiting Professorship; Northeastern Ohio Consortium (Medicine); Visiting Professor (1992)
Visiting Professorship; Pennsylvania State University (Nephrology); Visiting Professor (1992)
Visiting Professorship; Pennsylvania State University (Nephrology); Visiting Professor (1992)
Visiting Professorship; Yale University (Cardiology); Visiting Professor (1992)
Visiting Professorship; University of Michigan (Hypertension); Visiting Professor (1991)
Visiting Professorship; Medical College of Ohio (Medicine); Visiting Professor (1991)
Visiting Professorship; Albany Medical College (Cardiology and Medicine); Visiting Professor (1990)
Clinical Service; Hypertension Consultations (weekly, 1/2 day); Other (1990)
Visiting Professorship; West Virginia University (Nephrology); Visiting Professor (1988)
Clinical Service; Attending Physician, General Medicine, 2 months per year; Volunteer (1988)
Visiting Professorship; Henry Ford Hospital (Nephrology); Visiting Professor (1987)
Visiting Professorship; SUNY at Syracuse (Nephrology); Visiting Professor (1987)
Visiting Professorship; University of California, San Diego (Nephrology); Visiting Professor (1986)
Visiting Professorship; University of Kansas (Nephrology); Visiting Professor (1986)
Visiting Professorship; Yale University (Hypertension); Visiting Professor (1986)
Visiting Professorship; Temple University (Nephrology); Visiting Professor (1985)
Visiting Professorship; John Hopkins University School of Medicine (Nephrology); Visiting Professor (1984)
Visiting Professorship; Rutgers University (Physiology); Visiting Professor (1983)
Visiting Professorship; Johns Hopkins University School of Medicine (Nephrology); Visiting Professor (1983)
Visiting Professorship; Cleveland Clinic Foundation (Hypertension); Visiting Professor (1983)
Visiting Professorship; Albany Medical College (Nephrology); Visiting Professor (1982)
Visiting Professorship; NHLBI, NIH (Experimental Therapeutics) 5/82; Visiting Professor (1982)
Clinical Specialties:
Clinical Offices:
Insurance Accepted:
Contact Information
Erie County Medical Center 462 Grider Street Buffalo, NY 14215 Phone: (716) 898-5234 Fax: (716) 898-4493 Email: jizzo@buffalo.edu
Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB School of Medicine and Biomedical Sciences.
